SK16212000A3 - Farmaceutický prostriedok, spôsob jeho výroby, jeho použitie a výrobok s jeho obsahom - Google Patents

Farmaceutický prostriedok, spôsob jeho výroby, jeho použitie a výrobok s jeho obsahom Download PDF

Info

Publication number: SK16212000A3
Authority: SK; Slovakia
Prior art keywords: pharmaceutical composition; pharmaceutically acceptable; lamivudine; abacavir; zidovudine
Prior art date: 1998-04-29

Application number

SK1621-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Robin Currie

Sunil Jain

Allen Wayne Wood

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-29

Filing date

1999-04-26

Publication date

2001-07-10

1999-04-26 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2001-07-10 Publication of SK16212000A3 publication Critical patent/SK16212000A3/sk

Links

MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 title claims abstract description 49
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
229960004748 abacavir Drugs 0.000 title claims abstract description 46
LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 title claims description 14
239000000203 mixture Substances 0.000 claims abstract description 63
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims abstract description 41
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 41
229960001627 lamivudine Drugs 0.000 claims abstract description 39
229960002555 zidovudine Drugs 0.000 claims abstract description 37
238000000034 method Methods 0.000 claims abstract description 22
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 34
239000003814 drug Substances 0.000 claims description 19
235000019359 magnesium stearate Nutrition 0.000 claims description 17
239000002552 dosage form Substances 0.000 claims description 16
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
239000008108 microcrystalline cellulose Substances 0.000 claims description 13
229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 12
229940079832 sodium starch glycolate Drugs 0.000 claims description 10
239000008109 sodium starch glycolate Substances 0.000 claims description 10
229920003109 sodium starch glycolate Polymers 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 9
241000700605 Viruses Species 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 5
239000005022 packaging material Substances 0.000 claims description 5
206010038997 Retroviral infections Diseases 0.000 claims description 4
WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
229960000531 abacavir sulfate Drugs 0.000 claims description 3
238000004806 packaging method and process Methods 0.000 claims description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 2
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 2
229960001936 indinavir Drugs 0.000 claims description 2
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical group C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 2
229960000884 nelfinavir Drugs 0.000 claims description 2
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 2
229960000311 ritonavir Drugs 0.000 claims description 2
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
206010061598 Immunodeficiency Diseases 0.000 claims 1
208000029462 Immunodeficiency disease Diseases 0.000 claims 1
239000011248 coating agent Substances 0.000 claims 1
238000000576 coating method Methods 0.000 claims 1
230000007813 immunodeficiency Effects 0.000 claims 1
230000005764 inhibitory process Effects 0.000 claims 1
VIOAGOMGEZTUHG-UHFFFAOYSA-L magnesium;2-hydroxyacetate;octadecanoate Chemical compound [Mg+2].OCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O VIOAGOMGEZTUHG-UHFFFAOYSA-L 0.000 claims 1
230000001177 retroviral effect Effects 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract description 11
230000000840 anti-viral effect Effects 0.000 abstract description 6
230000002401 inhibitory effect Effects 0.000 abstract description 2
238000002360 preparation method Methods 0.000 abstract description 2
239000003826 tablet Substances 0.000 description 47
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
239000004480 active ingredient Substances 0.000 description 21
229940079593 drug Drugs 0.000 description 15
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
238000007906 compression Methods 0.000 description 12
230000006835 compression Effects 0.000 description 12
239000008187 granular material Substances 0.000 description 10
239000000843 powder Substances 0.000 description 9
241000124008 Mammalia Species 0.000 description 8
238000000926 separation method Methods 0.000 description 8
150000002148 esters Chemical class 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
239000008119 colloidal silica Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000011269 treatment regimen Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
229940075614 colloidal silicon dioxide Drugs 0.000 description 5
239000002245 particle Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
-1 [(-) BHCG Chemical compound 0.000 description 4
230000037396 body weight Effects 0.000 description 4
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
229940032147 starch Drugs 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000007907 direct compression Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229910021485 fumed silica Inorganic materials 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000007942 layered tablet Substances 0.000 description 3
238000011068 loading method Methods 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
239000002777 nucleoside Substances 0.000 description 3
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
239000012453 solvate Substances 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 2
241000282412 Homo Species 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
229910000503 Na-aluminosilicate Inorganic materials 0.000 description 2
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
229960004308 acetylcysteine Drugs 0.000 description 2
239000013543 active substance Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
239000000378 calcium silicate Substances 0.000 description 2
229910052918 calcium silicate Inorganic materials 0.000 description 2
235000012241 calcium silicate Nutrition 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 2
238000005461 lubrication Methods 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
235000014380 magnesium carbonate Nutrition 0.000 description 2
229940037627 magnesium lauryl sulfate Drugs 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000000429 sodium aluminium silicate Substances 0.000 description 2
235000012217 sodium aluminium silicate Nutrition 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
BMLMGCPTLHPWPY-REOHCLBHSA-N (4R)-2-oxo-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSC(=O)N1 BMLMGCPTLHPWPY-REOHCLBHSA-N 0.000 description 1
SYZIUAAQNFJPJY-UHFFFAOYSA-N 1,4-dihydro-3,1-benzoxazin-2-one Chemical compound C1=CC=C2COC(=O)NC2=C1 SYZIUAAQNFJPJY-UHFFFAOYSA-N 0.000 description 1
ASOMNDIOOKDVDC-UHFFFAOYSA-N 1h-indol-2-yl-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl]methanone Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=CC=C3C=2)CC1 ASOMNDIOOKDVDC-UHFFFAOYSA-N 0.000 description 1
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
BCSLVBZWCFTDPK-UDJQAZALSA-N 2-amino-9-[(2r,3r,4s)-3,4-bis(hydroxymethyl)oxetan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@H]1CO BCSLVBZWCFTDPK-UDJQAZALSA-N 0.000 description 1
MQYLVCBSCZPVMH-DTWKUNHWSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyridin-2-one Chemical compound O=C1C=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 MQYLVCBSCZPVMH-DTWKUNHWSA-N 0.000 description 1
UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
WTEBTXWQAAHZCX-XLNBVVSQSA-N 5-[(e)-2-bromoethenyl]-1-[(2r,4r)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidine-2,4-dione Chemical class S1[C@H](CO)OC[C@@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 WTEBTXWQAAHZCX-XLNBVVSQSA-N 0.000 description 1
WKVDSZYIGHLONN-RRKCRQDMSA-N 5-chloro-1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](F)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Cl)=C1 WKVDSZYIGHLONN-RRKCRQDMSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940124522 antiretrovirals Drugs 0.000 description 1
239000003903 antiretrovirus agent Substances 0.000 description 1
238000010923 batch production Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
229940072253 epivir Drugs 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229960004396 famciclovir Drugs 0.000 description 1
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960004413 flucytosine Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000002348 inosinate dehydrogenase inhibitor Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
KELNNWMENBUHNS-NSHDSACASA-N isopropyl (2s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2h)-carboxylate Chemical compound FC1=CC=C2NC(=O)[C@H](CC)N(C(=O)OC(C)C)C2=C1 KELNNWMENBUHNS-NSHDSACASA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940033984 lamivudine / zidovudine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229950006243 loviride Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229960001179 penciclovir Drugs 0.000 description 1
229960001476 pentoxifylline Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
229960003081 probenecid Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
238000005204 segregation Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940093257 valacyclovir Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Biophysics (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1621-2000A 1998-04-29 1999-04-26 Farmaceutický prostriedok, spôsob jeho výroby, jeho použitie a výrobok s jeho obsahom SK16212000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9809213.3A GB9809213D0 (en)	1998-04-29	1998-04-29	Pharmaceutical compositions
PCT/EP1999/002794 WO1999055372A1 (en)	1998-04-29	1999-04-26	Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine

Publications (1)

Publication Number	Publication Date
SK16212000A3 true SK16212000A3 (sk)	2001-07-10

Family

ID=10831228

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1621-2000A SK16212000A3 (sk)	1998-04-29	1999-04-26	Farmaceutický prostriedok, spôsob jeho výroby, jeho použitie a výrobok s jeho obsahom

Country Status (23)

Country	Link
EP (1)	EP1083932A1 (xx)
JP (1)	JP2002512979A (xx)
KR (1)	KR20010043128A (xx)
CN (1)	CN1411380A (xx)
AP (1)	AP2000001971A0 (xx)
AU (1)	AU4135599A (xx)
BR (1)	BR9910071A (xx)
CA (1)	CA2330391A1 (xx)
EA (1)	EA200000997A1 (xx)
EE (1)	EE200000646A (xx)
GB (1)	GB9809213D0 (xx)
HR (1)	HRP20000732A2 (xx)
HU (1)	HUP0101622A3 (xx)
ID (1)	ID26955A (xx)
IL (1)	IL139181A0 (xx)
IS (1)	IS5675A (xx)
NO (1)	NO20005418L (xx)
NZ (1)	NZ507745A (xx)
PL (1)	PL343710A1 (xx)
SK (1)	SK16212000A3 (xx)
TR (1)	TR200003157T2 (xx)
WO (1)	WO1999055372A1 (xx)
ZA (1)	ZA200005922B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875773B1 (en)	1998-05-29	2005-04-05	Ben M. Dunn	Combination therapy for treatment of FIV infection
CA2374198A1 (en) *	1998-05-29	1999-12-02	Maki Arai	Combination therapy for treatment of fiv infection
GB9820417D0 (en) *	1998-09-18	1998-11-11	Glaxo Group Ltd	Antiviral combinations
US7074417B2 (en) *	2000-10-13	2006-07-11	Advancis Pharmaceutical Corporation	Multiple-delayed release anti-viral product, use and formulation thereof
DE60219965T2 (de) *	2002-04-23	2008-01-17	Lupin Ltd., Mumbai	Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
TW200403061A (en) *	2002-06-04	2004-03-01	Glaxo Group Ltd	Pharmaceutical compositions
CN100335125C (zh) *	2003-06-03	2007-09-05	上海现代药物制剂工程研究中心	杀毒抗菌用长效干扰素喷鼻粉剂
WO2006114709A1 (en) *	2005-04-25	2006-11-02	Aurobindo Pharma Limited	Pharmaceutical compositions of antiretrovirals
WO2007013047A2 (en) *	2005-07-29	2007-02-01	Ranbaxy Laboratories Limited	Water-dispersible anti-retroviral pharmaceutical compositions
ES2279707B1 (es) *	2005-11-10	2008-06-01	Combino Pharm, S.L.	Formulaciones orales que comprenden 3'-azidonucleosidos.
US20110053884A1 (en) *	2007-10-02	2011-03-03	Schinazi Raymond F	Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase
GB2470494B (en) *	2008-01-17	2012-08-08	Univ Holy Ghost Duquesne	Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
PH12012501537A1 (en) *	2010-01-27	2018-02-07	Viiv Healthcare Co	Antiviral therapy
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
EP2822560A1 (en)	2012-03-05	2015-01-14	Cipla Limited	Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
CN104884063A (zh)	2012-10-23	2015-09-02	西普拉有限公司	抗逆转录病毒药物组合物
EP3007695B1 (en)	2013-06-13	2024-02-07	Akebia Therapeutics, Inc.	Compositions and methods for treating anemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY115461A (en) *	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9622681D0 (en) *	1996-10-31	1997-01-08	Glaxo Group Ltd	Pharmaceutical compositions

1998
- 1998-04-29 GB GBGB9809213.3A patent/GB9809213D0/en not_active Ceased
1999
- 1999-04-26 AU AU41355/99A patent/AU4135599A/en not_active Abandoned
- 1999-04-26 JP JP2000545569A patent/JP2002512979A/ja active Pending
- 1999-04-26 SK SK1621-2000A patent/SK16212000A3/sk unknown
- 1999-04-26 KR KR1020007012021A patent/KR20010043128A/ko not_active Withdrawn
- 1999-04-26 WO PCT/EP1999/002794 patent/WO1999055372A1/en not_active Ceased
- 1999-04-26 HR HR20000732A patent/HRP20000732A2/hr not_active Application Discontinuation
- 1999-04-26 CA CA002330391A patent/CA2330391A1/en not_active Abandoned
- 1999-04-26 ID IDW20002479A patent/ID26955A/id unknown
- 1999-04-26 NZ NZ507745A patent/NZ507745A/en unknown
- 1999-04-26 EP EP99924822A patent/EP1083932A1/en not_active Withdrawn
- 1999-04-26 IL IL13918199A patent/IL139181A0/xx unknown
- 1999-04-26 EE EEP200000646A patent/EE200000646A/xx unknown
- 1999-04-26 AP APAP/P/2000/001971A patent/AP2000001971A0/en unknown
- 1999-04-26 CN CN99807983A patent/CN1411380A/zh active Pending
- 1999-04-26 BR BR9910071-1A patent/BR9910071A/pt not_active IP Right Cessation
- 1999-04-26 TR TR2000/03157T patent/TR200003157T2/xx unknown
- 1999-04-26 HU HU0101622A patent/HUP0101622A3/hu unknown
- 1999-04-26 PL PL99343710A patent/PL343710A1/xx unknown
- 1999-04-26 EA EA200000997A patent/EA200000997A1/ru unknown
2000
- 2000-10-20 IS IS5675A patent/IS5675A/is unknown
- 2000-10-23 ZA ZA200005922A patent/ZA200005922B/xx unknown
- 2000-10-27 NO NO20005418A patent/NO20005418L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20010043128A (ko)	2001-05-25
NO20005418L (no)	2000-11-29
PL343710A1 (en)	2001-08-27
CN1411380A (zh)	2003-04-16
NO20005418D0 (no)	2000-10-27
ZA200005922B (en)	2001-10-23
EP1083932A1 (en)	2001-03-21
AU4135599A (en)	1999-11-16
HUP0101622A2 (hu)	2002-03-28
GB9809213D0 (en)	1998-07-01
IS5675A (is)	2000-10-20
EA200000997A1 (ru)	2001-06-25
BR9910071A (pt)	2000-12-26
WO1999055372A1 (en)	1999-11-04
EE200000646A (et)	2002-04-15
TR200003157T2 (tr)	2001-01-22
ID26955A (id)	2001-02-22
NZ507745A (en)	2004-07-30
JP2002512979A (ja)	2002-05-08
IL139181A0 (en)	2001-11-25
HRP20000732A2 (en)	2001-02-28
CA2330391A1 (en)	1999-11-04
HUP0101622A3 (en)	2003-09-29
AP2000001971A0 (en)	2000-12-31

Publication	Publication Date	Title
SK16212000A3 (sk)	2001-07-10	Farmaceutický prostriedok, spôsob jeho výroby, jeho použitie a výrobok s jeho obsahom
ES2308136T3 (es)	2008-12-01	Composiciones y procedimientos para la politerapia antiviral.
CN1103593C (zh)	2003-03-26	协同组合物
EP2051703B1 (en)	2010-07-21	Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
US6113920A (en)	2000-09-05	Pharmaceutical compositions
EP0941100B1 (en)	2003-05-28	Pharmaceutical compositions containing lamivudine and zidovudine
EP1567133B1 (en)	2007-05-02	Pharmaceutical antiviral compositions
US20050171127A1 (en)	2005-08-04	Pharmaceutical compositions comprising abacavir and lamivudine
CZ20003998A3 (cs)	2001-06-13	Farmaceutický prostředek
MXPA00010498A (en)	2001-09-07	Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
MXPA99004025A (en)	2000-02-02	Pharmaceutical compositions containing lamivudine and zidovudine
WO2000018383A2 (en)	2000-04-06	Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
NZ500868A (en)	2001-08-31	Antiviral combinations comprising 1592U89 and HIV protease inhibitors
HK1020880B (en)	2003-11-28	Pharmaceutical compositions containing lamivudine and zidovudine
US20050113394A1 (en)	2005-05-26	Pharmaceutical compositions